Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis-Reference-Cited by-同舟云学术

Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis

Published:2024-01-10 Issue:1184 Volume:100 Page:366-372
ISSN:0032-5473
Container-title:Postgraduate Medical Journal
language:en
Short-container-title:

Author:

Zhong Xinxin¹,Lin Ao²,Luo Jian¹,Li Yeqin¹,Chen Jinlan¹,Ning Chao¹,Cao Fu¹

Affiliation:

1. Department of Pulmonary and Critical Care Medicine, Red Cross Hospital of Yulin City , Yulin, Guangxi 537000 , China

2. Department of Cardiothoracic Surgery, Red Cross Hospital of Yulin City , Yulin, Guangxi 537000 , China

Abstract

Abstract Multidrug-resistant tuberculosis (MDR-TB) has become a critical challenge to public health, and the prevention and treatment of MDR-TB are of great significance in reducing the global burden of tuberculosis. How to improve the effectiveness and safety of chemotherapy for MDR-TB is a pressing issue that needs to be addressed in tuberculosis control efforts. This article provides a comprehensive review of the clinical application of new antituberculosis drugs in MDR-TB, aiming to provide a scientific basis for the prevention and treatment strategy of MDR-TB.

Funder

Science and Technology Bureau of Yulin City

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/pmj/article-pdf/100/1184/366/57742731/qgad140.pdf

Reference85 articles.

1. The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review;Harris;BMC Infect Dis,2016

2. Oxadiazole scaffolds in anti-tuberculosis drug discovery;De;Bioorg Med Chem Lett,2019

3. New tuberculosis drugs on the horizon;Cole;Curr Opin Microbiol,2011